Centaurus Therapeutics, Inc., San Francisco, California, USA.
Diabetes and Metabolism Research Center, Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
DNA Cell Biol. 2020 May;39(5):733-737. doi: 10.1089/dna.2020.5402. Epub 2020 Mar 16.
Ceramides have emerged as important regulators of tissue metabolism that play essential roles in cardiometabolic disease. They are potent biomarkers of diabetes and heart disease and are now being measured clinically as predictors of major adverse cardiac events. Moreover, studies in rodents reveal that inhibitors of ceramide synthesis prevent or reverse the pathogenic features of type 2 diabetes, nonalcoholic fatty liver disease, atherosclerosis, and cardiomyopathy. Herein the authors discuss inhibition of dihydroceramide desaturase-1, the final enzyme in the ceramide biosynthesis pathway, as a potential therapeutic approach to lower ceramides and combat cardiometabolic disease.
神经酰胺已成为组织代谢的重要调节剂，在心脏代谢疾病中发挥着重要作用。它们是糖尿病和心脏病的有效生物标志物，目前正在临床上作为主要不良心脏事件的预测指标进行测量。此外，啮齿动物研究表明，神经酰胺合成抑制剂可预防或逆转 2 型糖尿病、非酒精性脂肪性肝病、动脉粥样硬化和心肌病的发病特征。作者在此讨论了二氢神经酰胺去饱和酶-1（神经酰胺生物合成途径的最后一种酶）的抑制作用，作为降低神经酰胺和防治心脏代谢疾病的一种潜在治疗方法。
